The NSGO-9501/EORTC-5591 trial demonstrated the efficacy of chemoradiation in improving outcomes for women predominantly diagnosed with Stage I endometrial cancer exhibiting Grade 3 and/or deep invasion.[ 13 ] This trial, along with the ongoing ManGO Iliade-III trial, pooled their data, revealing a significant enhancement in recurrence-free survival and a suggestive trend toward improved overall survival when chemotherapy was added to radiotherapy.
← all excerpts
Adjuvant Therapy for Endometrial Cancer in the Era of Molecular Classification.
1
—
—